

19<sup>th</sup> December, 2019

The Manager, Listing Department  
National Stock Exchange of India Ltd.  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051

BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400 001

NSE Symbol: PANACEABIO

BSE Scrip Code: 531349

**Re.: Press Release – Panacea Biotec receives USD 24.32 Million Award of Pentavalent Vaccine from U.N. Agencies**

Dear Sir,

Panacea Biotec Ltd. is pleased to announce that the company has received Awards worth USD 24.32 Million (Over INR 170 Crores) from U.N. Agencies (UNICEF and PAHO) for supply of its Easyfive-TT, a fully liquid WHO prequalified wP based Pentavalent Vaccine (DTwP-HepB-Hib).

UNICEF award is for calendar year 2020 and award of PAHO is for three (3) calendar years i.e. 2020-2022.


Pediatric vaccination plays an important role to achieve Sustainable Development Goals set by the United Nations, in particular the target to reduce under-five mortality rate to less than 25 per 1000 live births. Pentavalent vaccine protects children against five deadly diseases; Diphtheria, Tetanus, Pertussis, Hepatitis B and invasive infections caused by Haemophilus Influenza Type b – becoming the foundation of paediatric immunization programs across the world.

Easyfive-TT was introduced by Panacea Biotec as world's first fully liquid wP-based pentavalent vaccine in Indian market in 2005. With WHO prequalification in 2008, over 100 million doses have been supplied to more than 50 countries globally. Easyfive-TT is ready for use without further preparation by healthcare workers in the field, which offers major healthcare advantages in countries with challenging infrastructure and hygiene problems.

A copy of the Press Release being issued to the media, etc. in this regard is enclosed for your kind reference and record please.

Kindly acknowledge the receipt.

Thanking you,  
Sincerely yours,  
for **Panacea Biotec Ltd.**

  
**Devender Gupta**  
Chief Financial Officer and Head IT  
Encl. As Above



**Panacea Biotec Ltd.**

CIN: L33117PB1984PLC022350

Registered Office: Ambala-Chandigarh Highway, Lalru - 140 501, Punjab, India. Ph.: +91-1762-505900, Fax: +91-1762-505906.  
e-mail: corporate@panaceabiotec.com website: www.panaceabiotec.com

New Delhi | Thursday, 19<sup>th</sup> December, 2019

### Easyfive-TT Injects Cheer for Panacea Biotec


#### **Panacea Biotec receives USD 24.32 Million Award of Pentavalent Vaccine from U.N. Agencies**

Panacea Biotec, one of the India's leading Biotechnology Company received Awards worth **USD 24.32 Million** (Over INR 170 crores) from U.N. Agencies (UNICEF and PAHO) for supply of its Easyfive-TT, a fully liquid WHO prequalified wP based Pentavalent Vaccine (DTwP-HepB-Hib).

UNICEF award is for calendar year 2020 and award of PAHO is for three (3) calendar years i.e. 2020-2022.

Pediatric vaccination plays an important role to achieve Sustainable Development Goals set by the United Nations, in particular the target to reduce under-five mortality rate to less than 25 per 1000 live births. Pentavalent vaccine protects children against five deadly diseases; Diphtheria, Tetanus, Pertussis, Hepatitis B and invasive infections caused by Haemophilus Influenza Type b – becoming the foundation of paediatric immunization programs across the world.

Easyfive-TT was introduced by Panacea Biotec as world's first fully liquid wP-based pentavalent vaccine in Indian market in year 2005. With WHO prequalification in 2008, over 100 million doses have been supplied to more than 50 countries globally. Easyfive-TT is ready for use without further preparation by healthcare workers in the field, which offers major healthcare advantages in countries with challenging infrastructure and hygiene problems.



**Panacea Biotec Ltd.**

CIN: L33117PB1984PLC022350

Registered Office: Ambala-Chandigarh Highway, Lalru - 140 501, Punjab, India. Ph.: +91-1762-505900, Fax: +91-1762-505906.  
e-mail: corporate@panaceabiotec.com website: www.panaceabiotec.com



**Panacea Biotec**

*Innovation in support of life*

Panacea Biotec has contributed significantly for Children's Health and has partnered with WHO, UNICEF & PAHO in their efforts to maximize coverage of vaccines under the Expanded Program on Immunization (EPI) in developing countries. The Company has pioneered in development of wP based fully-liquid combination vaccines and has launched:

- **Ecovac** (Diphtheria, Wholecell Pertussis, Tetanus, Hepatitis B),
- **Easyfour** (Diphtheria, Wholecell Pertussis, Tetanus and Hib),
- **Easyfive-TT** (Diphtheria, Whole cell Pertussis, Tetanus, Hepatitis B and Hib),
- **Easysix** (Diphtheria, Whole cell Pertussis, Tetanus, Hepatitis B, Hib and IPV) – the world's first and only wP-IPV hexavalent vaccine to meet programmatic needs of evolving immunization programs.

As a responsible and reliable partner, Panacea Biotec thus contributes to the success of the Global Alliance for Vaccines and Immunization (GAVI Alliance) in accelerating access to these vaccines across the globe.

**Dr. Rajesh Jain, Managing Director, commented,** "Our continued focus on high-quality standards and supply sustainability has helped drive and strengthen good-will for Panacea Biotec in the UN agencies-led market. EasyFive-TT has further proved its ability to continuously attract customer interest, validated its role as a valuable and dependable product in our portfolio."

Panacea Biotec is a leading pharmaceutical and Biotechnology Company with established Research, Manufacturing and Marketing capabilities, The Company has been ranked as the fastest growing company in its represented market share by All India Organization of Chemists & Druggists (AIOCD) in September 2019.

The Company has been awarded with the prestigious "India Innovation Award – Top 50" by Clarivate Analytics (Thomson Reuters) for the years 2015 & 2016.

The product portfolio includes innovative products in therapeutic areas of Oncology, Organ Transplantation, Nephrology, Diabetes, Osteoporosis, Cardiovascular diseases and Pediatric vaccines. Company has introduced its products in around 30 countries across the World including USA, Germany and Russian Federation through a combination of strategic collaborations and direct presence in select geographies. The Company has research collaborations with leading national and international organizations. The company has around 2750 employees.



**Panacea Biotec Ltd.**

CIN: L33117PB1984PLC022350

Registered Office: Ambala-Chandigarh Highway, Lalru - 140 501, Punjab, India. Ph.: +91-1762-505900, Fax: +91-1762-505906.

e-mail: corporate@panaceabiotec.com website: www.panaceabiotec.com




**Panacea Biotec**

*Innovation in support of life*

For more information, please contact:

<b>For Investors:</b>	<b>For Media:</b>
Mr. Devender Gupta Chief Financial Officer and Head Information Technology Tel: + 91-11-4167900 Ext.1225 41578011 (Direct) Mobile : + 91 98109 04102 Email: devendergupta@panaceabiotec.com	Mr. P.D. Karan Vice President Corporate Communication & Business Development Tel: + 91-11-4167900 Ext.1406 41578080 (Direct) Mobile : + 91 9810500539/9312693040 Email: pdkaran@panaceabiotec.com



**Panacea Biotec Ltd.**

CIN: L33117PB1984PLC022350

Registered Office: Ambala-Chandigarh Highway, Lalru - 140 501, Punjab, India. Ph.: +91-1762-505900. Fax: +91-1762-505906.  
e-mail: corporate@panaceabiotec.com website: www.panaceabiotec.com